Huan Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huan Bao has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bei Zhang
Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China
1 shared publication Can Cui
Department of Neurology Shanghai East Hospital School of Medicine, Tongji University Shanghai China
1 shared publicationFeifei Wu
Department of Clinical Laboratory, Shanghai Gongli Hospital, The Second Military Medical University, Shanghai, China
1 shared publication- Gang Li
Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China
1 shared publication Haifeng Ji
Department of Neurology, Shanghai Gongli Hospital, The Second Military Medical University
1 shared publication- Hao Shen
Department of Neurology Shanghai East Hospital School of Medicine, Tongji University Shanghai China
1 shared publication
Latest Publications
- 17 April 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (9) , 2922-2926
Association of HMOX‐1 with sporadic Alzheimer’s disease in southern Han Chinese
Background and purpose: The aim of this study was to discover the associations between HMOX‐1 and Alzheimer's disease (AD).Methods: A total of 500 AD patients and 500 healthy controls were recruited in this study. Polymer chain reaction was used.Results: There was a statistically significant difference between AD patients and controls in both the dominant and recessive models of HMOX‐1 rs2071746 after adjustment for age, gender and education (dominant model: p = 0.047, odds ratio [OR] 1.34, 95% confidence interval [CI] 1.00–1.78, adjusted; recessive model: p = 0.049, OR 1.34, 95% CI 1.00–1.80, adjusted). There was also a trend for an association between the dominant model and late‐onset AD after adjustment for age, gender and education (dominant model: p = 0.084, OR 1.37, 95% CI 0.96–1.95, adjusted).Conclusions: We found an association between the dominant and recessive models of HMOX1 rs2071746 and AD.
- 17 April 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (9) , 2922-2926
Association of HMOX‐1 with sporadic Alzheimer’s disease in southern Han Chinese
Background and purpose: The aim of this study was to discover the associations between HMOX‐1 and Alzheimer's disease (AD).Methods: A total of 500 AD patients and 500 healthy controls were recruited in this study. Polymer chain reaction was used.Results: There was a statistically significant difference between AD patients and controls in both the dominant and recessive models of HMOX‐1 rs2071746 after adjustment for age, gender and education (dominant model: p = 0.047, odds ratio [OR] 1.34, 95% confidence interval [CI] 1.00–1.78, adjusted; recessive model: p = 0.049, OR 1.34, 95% CI 1.00–1.80, adjusted). There was also a trend for an association between the dominant model and late‐onset AD after adjustment for age, gender and education (dominant model: p = 0.084, OR 1.37, 95% CI 0.96–1.95, adjusted).Conclusions: We found an association between the dominant and recessive models of HMOX1 rs2071746 and AD.
- Open Access
- 2 October 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 569977
Exosomes Derived From CircAkap7-Modified Adipose-Derived Mesenchymal Stem Cells Protect Against Cerebral Ischemic Injury
Background: Cerebral ischemic injury is a complicated pathological process. Adipose-derived stromal cells (ADSCs) have been used as a therapeutic strategy, with their therapeutic effects chiefly attributed to paracrine action rather than trans-differentiation. Studies have shown that circAkap7 was found to be downregulated in a mouse model of transient middle cerebral artery occlusion (tMCAO). Methods: To explore whether exosomes derived from circAkap7-modified ADSCs (exo-circAkap7) have therapeutic effects on cerebral ischemic injury, a mouse model of tMCAO, as well as an in vitro model of oxygen and glucose deprivation-reoxygenation (OGD-R) in primary astrocytes, were used. Results: Results showed that treatment with exo-circAkap7 protected against tMCAO in mice, and in vitro experiments confirmed that co-culture with exo-circAkap7 attenuated OGD-R-induced cellular injury by absorbing miR-155-5p, promoting ATG12-mediated autophagy, and inhibiting NRF2-mediated oxidative stress. Conclusion: We demonstrate here that exo-circAkap7 protected against cerebral ischemic injury by promoting autophagy and ameliorating oxidative stress.
- 2 October 2020
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 569977
Open AccessExosomes Derived From CircAkap7-Modified Adipose-Derived Mesenchymal Stem Cells Protect Against Cerebral Ischemic Injury
Background: Cerebral ischemic injury is a complicated pathological process. Adipose-derived stromal cells (ADSCs) have been used as a therapeutic strategy, with their therapeutic effects chiefly attributed to paracrine action rather than trans-differentiation. Studies have shown that circAkap7 was found to be downregulated in a mouse model of transient middle cerebral artery occlusion (tMCAO). Methods: To explore whether exosomes derived from circAkap7-modified ADSCs (exo-circAkap7) have therapeutic effects on cerebral ischemic injury, a mouse model of tMCAO, as well as an in vitro model of oxygen and glucose deprivation-reoxygenation (OGD-R) in primary astrocytes, were used. Results: Results showed that treatment with exo-circAkap7 protected against tMCAO in mice, and in vitro experiments confirmed that co-culture with exo-circAkap7 attenuated OGD-R-induced cellular injury by absorbing miR-155-5p, promoting ATG12-mediated autophagy, and inhibiting NRF2-mediated oxidative stress. Conclusion: We demonstrate here that exo-circAkap7 protected against cerebral ischemic injury by promoting autophagy and ameliorating oxidative stress.
- Open Access
- 1 January 2018
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 16
Serial electromyographic findings in Guillain-Barré syndrome patients
We sought to investigate electromyographic characteristics of Guillain-Barré syndrome (GBS) patients in the recovery phase by using serial electromyography (EMG). We included seven GBS patients and assessed their neurologic function at admission and 2, 3 and 6 months post onset using Hughes Functional Grading Scale scores. All patients underwent serial electromyographic assessment of compound muscle action potentials (CMAPs), mean conduction velocity (MCV), and distal motor latency (DML) of peripheral nerves. F wave was recorded of the median nerve and ulnar nerve. All seven patients had a Hughes Functional Grading Scale score between 3 and 6 at admission, while three patients at 2 months, one patient at 3 months, and no patient at 6 months post GBS onset had a Hughes Functional Grading Scale score between 3 and 6 (P < 0.05). No F wave was elicited in 41.7% (20/48) of the motor nerves examined at admission, which declined to 25% at 6 months post GBS onset. Decreased amplitude in CMAPs was seen in 50% (24/48) of the motor nerves examined at admission, which decreased to 25% at 6 months (P < 0.05). Moreover, 60.4% (29/48) of the motor nerves showed abnormal abduction velocity, which declined to 0% at 3 and 6 months post GBS onset (P < 0.01). In conclusion, GBS patients exhibit a variable course in recovery of electromyographic parameters, and amplitude in CMAPs cannot fully reflect recovery of muscle tone. Conduction block is reversible and in line with rapid muscle tone recovery.
- 1 January 2018
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 16
Open AccessSerial electromyographic findings in Guillain-Barré syndrome patients
We sought to investigate electromyographic characteristics of Guillain-Barré syndrome (GBS) patients in the recovery phase by using serial electromyography (EMG). We included seven GBS patients and assessed their neurologic function at admission and 2, 3 and 6 months post onset using Hughes Functional Grading Scale scores. All patients underwent serial electromyographic assessment of compound muscle action potentials (CMAPs), mean conduction velocity (MCV), and distal motor latency (DML) of peripheral nerves. F wave was recorded of the median nerve and ulnar nerve. All seven patients had a Hughes Functional Grading Scale score between 3 and 6 at admission, while three patients at 2 months, one patient at 3 months, and no patient at 6 months post GBS onset had a Hughes Functional Grading Scale score between 3 and 6 (P < 0.05). No F wave was elicited in 41.7% (20/48) of the motor nerves examined at admission, which declined to 25% at 6 months post GBS onset. Decreased amplitude in CMAPs was seen in 50% (24/48) of the motor nerves examined at admission, which decreased to 25% at 6 months (P < 0.05). Moreover, 60.4% (29/48) of the motor nerves showed abnormal abduction velocity, which declined to 0% at 3 and 6 months post GBS onset (P < 0.01). In conclusion, GBS patients exhibit a variable course in recovery of electromyographic parameters, and amplitude in CMAPs cannot fully reflect recovery of muscle tone. Conduction block is reversible and in line with rapid muscle tone recovery.